Replies to post #251773 on Biotech Values

[DewDiligence]

No Daxxify therapeutics sales were booked in 1Q24. The formal Daxxify launch in cervical dystonia was announced today (#msg-174389042).

1Q24 was a weak quarter for the entire dermal-filler market. ABBV's 1Q24 Juvederm sales were -16% YoY.